The high costs often associated with treatments for rare diseases can make it challenging for patients to gain access to these life-changing therapies. PRECISIONheor experts have led research in a number of innovative studies on rare diseases to help get these treatments into the hands of the patients that need them the most.
This month PRECISIONheor would like to highlight the work and expertise of Senior Director Ivar Jensen.
Despite 100-year since its discovery, insulin – a life-saving medicine – remains inaccessible to millions around the world, owing to limited availability and high cost. Insulin is manufactured in just 20 countries worldwide, leaving all the other countries dependent on imports to meet the needs of their patients with diabetes.
Quantification of temporal transmission potential of an infectious disease has been a challenge. Most mathematical models assume that the transmission rate of an infectious disease either does not vary over time or change in fixed pre-determined adhoc ways.
Several clinical scoring systems have gradually emerged for liver injury diagnosis, but certain serious inherent deficiencies currently limit their predictive value. Precision's Anuj Mubayi and co-author Aditi Ghosh report on their first of its kind study to use mathematical modeling to provide an accurate novel prognosis method to improve tools for diagnosis and clinical management of drug-induced acute liver injury and heart-attack-influenced ischaemic hepatitis liver injury.
With drug pricing becoming a hot-button issue in recent years, the spotlight has focused on cost effectiveness models as a means of reducing health care spending, and pharmaceutical spending in particular. Precision's Jacquelyn Chou argues that the current cost effectiveness model is too narrow, and identifies additional elements of value that should be included to provide a better voice for patients in the science, rather than serving as a cost-containment tool.
Join us for "Methodological Borrowing versus Conceptual Blending: Reengineering Health Economics Processes with Modeling and Simulations," Featuring PRECISIONheor's Ross Maclean and Anuj Mubayi.
Want a glimpse at some of the groundbreaking work PRECISIONheor experts have recently contributed to in the CNS/Neuro Space to help get life-saving treatments in the hands of patients that need them the most?
This month PRECISIONheor would like to highlight the work and expertise of Vice President Jacki Chou.
This month PRECISIONheor would like to highlight the work and expertise of Senior Director Naomi Sacks.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
